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Improvements in drug design have historically been centered around structure-based optimization of mole-
cule specificity for a targeted protein, in an effort to reduce unintentional binding to other proteins and off-
target effects. Although the ‘‘one-to-one’’ drug design strategy has been successful in impairing function
of targets associated with a number of diseases, recent reports of drug promiscuity, which are a potential
source of adverse reactions in patients, make a case to refine the drug design strategy such that it includes
an awareness of multiple interactions from both ligand and protein perspectives. Polypharmacology and
chemical biology studies are amassing interaction data at rapid rates, and the integration of such data into
an interpretable model requires zooming our perspective out from the single ligand-target level to the larger
network-wide level. We review some of the recent developments in systems-level research for drug design
and discovery, and discuss the directions that some drug design efforts are heading toward.Single-Target Drug Design and Side Effects
The information obtained from analysis of protein three-dimen-
sional structure often kick-starts the modern drug design
process, providing information for designing small molecules
that are complementary to the shape of an investigated protein.
Thus, the basic idea here is to take advantage of complemen-
tarity built into designed small molecules to inactivate the protein
function and stop downstream cellular processes. Subsequent
design revisions are typically aimed at optimizing the binding,
reducing molecular weight, or increasing lipophilicity, which all
improve the molecule’s drug-like properties. With the assistance
of computational techniques, a number of drugs have been
refined with this mindset, and a number of reviews have dis-
cussed the impact made by computational drug design
(Schneider and Fechner, 2005; Jacoby, 2011).
Although an appreciable number of drugs have been designed
with a particular protein as the target, and although the desired
effects of drugs are observable in a statistically significant
manner during early in vitro and in vivo development stages,
unexpected side effects continue to be a problem. This is
frequently a contributor to failure in clinical trials, where the
drug that showed success in vitro fails to work as intended
when placed in a more complex in vivo environment. The fact
that drug side effects exist indicates that there is something in
the underlying assumptions about drug design that needs to
be questioned and refined. Immediately, several questions
come to mind. Even though a drug has been designed to target
a single protein, it is important to question whether such a design
is truly optimal for inhibiting a disease processwhich involves the
orchestration of multiple receptors and proteins passing signals
to each other. Additionally, is the assumption of a simple linear
signaling cascade from ligand binding to the effect a valid
one? Finally, is the designed drug molecule truly binding to
only the intended protein?
In recent drug design, we have adjusted our mindset from the
traditional one-protein-one-ligand model to incorporate the viewChemistry & Biolthat the underlying response mechanisms activated by the
ligand stimulation are a network of processes, and that it is this
network or systems biology level of understanding that needs
to be considered for advancing our knowledge of the conse-
quences of single-target drug design, including side effects.
Much like the Internet that is a dynamic, multiple connection net-
work system to transmit information, we believe the next gen-
eration of molecule design will need to consider a more dynamic,
multipathway system that a drug can take to exert an effect.
Here, we will introduce ligand multi-targeting properties and
how the properties can be used to develop a different kind of
small molecule effectors that intentionally interact at the network
level rather than at the single target level. We will illustrate our
ideas with recent examples that highlight the issue and provide
potential solutions, by drawing from both computational and
chemical biology efforts.
Multiple Interactions between Ligands
and Target Proteins
As mentioned, thus far drug design strategies by and large
employed the one-protein-one-ligand model. However, in the
past decade, the emergence of chemical biology is increasingly
influencing the directions that drug design proceeds in, because
it provides a platform for improving our understanding of how
small molecules impact the underlying functional frameworks
that connect intracellular macromolecules (Schreiber, 2005).
Chemical biology approaches are being applied in a wide variety
of research model organisms including yeast (Hu¨bel, 2009),
chickens (Yamamoto et al., 2011), and mice (Chen et al.,
2011). In addition to chemical biology, polypharmacology
(MacDonald et al., 2006) has also gained attention in recent
years as efforts to understand biological network signaling
cascades that are perturbed by drug stimulation have increased.
Such studies demonstrate the ‘‘many-to-many’’ nature of
compound-protein interactions, as opposed to the traditional
‘‘one-to-one’’ model, and it is believed that drug side effectsogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 23
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unexpected reactions are complex; molecular shape and prop-
erties, proteins’ allosteric behavior, pathway perturbation, and
pharmaco-kinetics/dynamics are all influential.
First, we need to consider the extent to which a target protein
will bind to a wide variety of ligands. Hopkins (2007) performed
a large-scale systematic study of polypharmacology from
a protein perspective, finding that many G protein-coupled
receptors (GPCRs) were able to bind a large number of ligands.
In addition to GPCRs such as histamine H2 and the a2B adren-
ergic receptor, three types of cytochrome P450 enzymes and
protein kinase C-delta, among many other proteins, have also
been reported to bind to over 100 ligands at an activity threshold
of 10 mM (Paolini et al., 2006).We briefly evaluated target promis-
cuity by investigating ligand specificity of proteins found in the
ChEMBL SARfari databases (http://www.ebi.ac.uk/chembl),
identifying the targets in which at least 100 ligandswere reported
with exact nanomolar inhibitory values (GPCRs: Ki; kinases:
IC50). The numbers of proteins matching this criterion were 129
for GPCRs and 90 for kinases. This calculation is an underesti-
mate of target promiscuity, as we excluded ligands with inexact
nM or uM inhibitory values and set a rather high threshold for the
number of protein ligands, which resulted in excluding a number
of less promiscuous yet still functionally important proteins
such as GPCRs EDG 1/2/3/4/7 involved in endothelial differenti-
ation and CCR 1/2/4/5/8 chemokine receptors, and apoptosis
pathway kinases DAPK 1/2/3 and DYRK 1A/2/3.
One should also consider the extent to which drug molecules
designed for a particular protein are actually promiscuous and
bind to many proteins. In previous research, we developed
the GPCR-ligand database (GLIDA) (Okuno et al., 2008), a
GPCR-specific resource that has cataloged GPCR-ligand inter-
actions, containing visualization maps that both demonstrate
polypharmacology and allow one to rapidly identify promiscuous
compounds such as clozapine, an example of a well-known
antipsychotic drug that is considered ‘‘effectively promiscuous’’
(Hopkins et al., 2006). Using ChEMBL, we scanned both GPCR
and kinase interaction data to get a first-hand glimpse into
small molecule and ligand promiscuity. Based on the proteins
from the above analysis, we found that 19,528 of 33,237 ligands
(59%) in the kinase database have exact nanomolar inhibitory
values. When we eliminated those ligands that were bound
to only a single target, there were still 6,942 promiscuous mole-
cules (36%) left. For ChEMBL’s GPCR database, 35,090 of
118,013 (30%) molecules bind to the reduced set of multi-ligand
receptors. Even after filtration of single-target ligands, the set of
GPCR ligands still contained 18,564 (53%) promiscuous, multi-
target molecules. These values should be considered as an
underestimate of the situation as the search conditions were
highly constrained.
Thus, the databases accumulating chemical biology data
reveal a more realistic view of many-to-many interactions be-
tween proteins and ligands, suggesting that consideration of
multiple interactions could be a key to improving drug design
strategies.
Widening the Vision of Scope to the Network Level
These target and ligand promiscuities can be regarded as a
very reasonable mechanism for subtle control of complicated24 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rbiological systems because the existence of multiple combina-
tions of the limited number of endogenous ligands and target
proteins is a potential reason for explaining the diversity of input
patterns into the downstream signaling pathways, suggesting
that understanding and controlling of the promiscuities is a
critical issue for drug design. Up to the present, ligand promis-
cuity has not been the explicit intent of drug design. Hence,
the idea of polypharmacology suggests that principles that
govern drug design should be reconsidered, and that drug
design should be undertaken with a broader perspective.
Another way of thinking about the opportunity presented by
evidence of polypharmacology is that we should attempt to
design ‘‘network-oriented’’ drugs. Considering entire networks,
even social or logistical, allows one to derive a ‘‘context’’ for
a subset of the network, where the context is often derived
dynamically from the neighboring nodes. For network-oriented
drugs, the context is the signaling network with multiple entry
points, a design philosophy in sharp contrast to the ‘‘network-
less’’ (single molecular target) designs that are intuitive when
limited to a one-to-one local scope. Similar arguments, ques-
tioning whether the use of the reductionist approach typically
applied in chemistry and physics is appropriate for drug design,
given that reduction to network pieces does not provide direc-
tions for network reassembly, were made recently (Maggiora,
2011).
Once we accept that drug design needs to incorporate
a ‘‘many-to-many’’ network approach, the next issue to solve
is how to create and validate such a ligand-protein network.
Next, we discuss several related computational drug discovery
methods, including a network-oriented approach with experi-
mental validation.
A New Drug Design Approach Based on Machine
Learning of Network-Wide Interaction Space between
Chemistry and Biology
GPCRs are involved in vision, smell, immune system activity, and
many other high-level physiological functions. Binding of extra-
cellular ligands to GPCRs affects cellular internal downstream
signaling, which has a crucial impact on the function of an
organism. The downstream signal processes are complex
nonlinear relationships, reaffirming our need to shift the ligand
designmindset from one-to-one to a larger network perspective.
Although at least 300 GPCRs are of therapeutic interest, drugs
currently available on the market target <10% of them (Okuno
et al., 2008) and much of the GPCR-ligand interaction space
remains to be explored. Using the 39,000 interactions available
in GLIDA for exploration of new regions in GPCR interaction
space not only uncovers new polypharmacological interactions
that could be contributing to drug side effects, but equally
important, represents the potential for identification of starting
points to develop new drugs with alternative scaffolds and
binding modes.
In a recent report (Yabuuchi et al., 2011), we proposed a drug
design concept, ‘‘Chemical Genomics-Based Drug Design’’
(CGBDD) for incorporating system-level multi-interaction
networks connecting chemistry and biology. To better under-
stand GPCRs from a systems perspective, we implemented a
new method for the computational prediction of novel GPCR-
ligand interactions, so called polypharmacological interactions.ights reserved
Figure 1. Complexity of Interaction Networks
Using known GPCR-ligand interactions, chemical genomics-based virtual screening was applied to discover novel interactions. When a GPCR-ligand interaction
is predicted at a bioactivity of 10 uM, a line between the GPCR and ligand is drawn in the interaction network. The resulting network, including known interactions,
demonstrates the complexity of interactions between chemical and biological spaces, and reinforces the need to shift the drug design strategy from ‘‘one-ligand-
one-protein’’ to ‘‘many-to-many.’’ The node color indicates the classes that compounds and GPCRs belong to (blue, amines; red, peptides; yellow, prostanoids;
green, nucleotides). The links colored from green to yellow to red indicate increasing confidence in the GPCR-ligand interaction, with a number of interclass
GPCR-ligand interactions exhibiting high predictive confidence.
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technique that leverages an interaction database for construc-
tion of amodel that accurately and compactly expresses interac-
tion patterns, such that the model has sufficient predictive
performance in translational testing. Although the idea of multi-
interaction data mining has been explored by several other
groups (Jacob and Vert, 2008; Wassermann et al., 2009), only
a very limited number of computational results have actually
been tested in experimental assays.
Although massive HTS studies are now possible, it is impor-
tant that drug discovery costs do not inflate simply because it
is easy to perform all possible assays. Thus, virtual screening
(VS) will become essential for efficiently reducing the number
of possible chemical candidates and bioactivities to assay.
However, the existing widely-used VS approaches are based
only on a one-to-one mindset, such as structure-based VS
(SBVS) and ligand-based VS (LBVS) methods. The CGBDD is
a drug design concept for leveragingmultiple compound-protein
interaction networks (Figure 1), and has been implemented to
develop a virtual screening method, called CGBVS (Yabuuchi
et al., 2011). The CGBVS approach requires less computational
time and complexity than existing SBVS methods, and over-Chemistry & Biolcomes problems encountered when performing LBVS for
orphaned receptors. Its goal is to efficiently mine the broad,
global chemical data space before using SBVS or LBVS with
a reduced number of drug scaffolds.
As mentioned at the beginning, recent in silico development of
drug leads and pharmaceuticals is being aided by the use of
computational techniques, and in the CGBVS approach we
employ machine learning, an active research field that develops
computational algorithms to extract statistically meaningful
information from large data sets. For those unfamiliar with
machine learning, it is easy to think of how a human child learns
to distinguish colors or shapes, after which they can cluster
new, unseen objects of ‘‘similar’’ color or shape together.
Thus, machine learning is a critical tool for the extraction and
representation of patterns existing in protein-ligand interactions
that can then be subsequently applied to drug lead discovery
and optimization.
Below, we briefly describe the CGBVS interaction prediction
procedure (Figure 2). For proteins in known and hypothetical
query interaction pairs, an analysis technique counting the
frequency of all dipeptide sub-sequences is applied; no struc-
tural information is required. We apply vector representation toogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 25
Figure 2. Roadmap for Systems-Level Drug Design
Similar to the CGBVS method that can utilize protein and ligand promiscuity, the incorporation of multiple interactions (polypharmacology and chemical
biology) will be a key for advancements in drug design. Systems-level awareness of chemical and biological processes and the feedback resulting from
clinical application will provide constraints to guide future generations of molecule design for producing medicines that are more personal and contain fewer side
effects.
Chemistry & Biology
Minireviewdescribe a ligand’s chemical structure and physicochemical
properties, such as atom counts, topology patterns, connectivity
frequencies, electrostatic properties, lipophilic character, and
other measurable types of information. For known (non-)interac-
tions, we also create a piece of information (‘‘bind’’, ‘‘non-bind’’)
representing bioactivity at a modifiable threshold of 10 mM. The
various pieces of information are concatenated per interaction
example, and all examples are combined to form the dataset
used for predictive model construction. We tested CGBVS
against pure SBVS and LBVS methods using statistical valida-
tion techniques and obtained improved prediction performance.
This result indicates that this representation of chemical-protein
interactions is effective in identifying frequent patterns in physi-
cochemical properties in order to model complex interactions,
and the machine learning approach provides a way to analyze
the nonlinear interaction data in such a way that different scaf-
folds can still be analyzed and clustered because of their similar
physicochemical characteristics. It provides a new opportunity
to perform reverse design from desired physicochemical char-
acteristics to potential scaffolds, which the medicinal chemist
can then optimize.
Using the full set of interactions in the GLIDA database, we
used the above procedure to derive a model for prediction of
novel GPCR ligands. Using the external Bionet chemical library
(Key Organics Ltd., Cornwall, UK), the top 30 novel b2AR interac-
tions predicted by CGBVS were tested in calcium mobilization
assays. Of those candidates, 9 of 30 compounds had EC50 or
IC50 values in the nM–mM range. With a similar procedure,
cAMP assays confirmed novel interactions in 3 of 20 neuropep-
tide type 1 (NPY1R) candidates that we predicted. Changing the
focus fromGPCRs to kinases, we performed similar experiments
for epidermal growth factor receptor (EGFR) and cyclin-depen-
dent kinase 2 (CDK2), which are being considered as targets26 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rfor anticancer therapy. Off-chip mobility shift assays resulted in
novel molecule interaction hit rates of 25% (EGFR, 5/20) and
10% (CDK2, 2/20). These hit rates are improvements relative
to the typical success rates encountered when screening entire
chemical libraries, although even more importantly, many of the
assay hits were compounds with scaffolds different from the
known ligands for each of the targets. All of the interactions
and novel scaffolds uncovered are published (Yabuuchi et al.,
2011). As the same technique was applicable to GPCRs,
kinases, ion channels, and other types of proteins, we anticipate
its concept will be repeatedly applied in the paradigm shift
from one-protein-one-ligand to a more complete, systems-level
multi-interaction network.
A recent related study described a ligand-based approach to
predict ligand-protein binding propensities by using no protein
sequence information but rather only a database of existing
ligands (Keiser et al., 2009). The success of this method
reiterates the importance of the many-to-many drug design
strategy. One major strength of the CGBDD philosophy is
that it can characterize multiple compound-protein interactions
to not only explore biological space and find new targets for
existing drugs (polypharmacology), but also explore chemical
space and find new drugs for existing targets (chemical
biology). Equally important, the CGBVS method has the ability
to discover novel scaffolds in unexplored chemical regions
through effective utilization of existing compound-protein inter-
action patterns, which can link systems biology and systems
chemistry.
Into the Future
A vast amount of bioassay data is now accumulating in data-
bases such as PubChem. The massive screening data could
expand our knowledge regarding chemical-biological interactionights reserved
Figure 3. Compound-Prediction Interaction Scheme
The CGBVS ligand-protein interaction discovery method (center) is a change in exploring the interface between chemistry and biology, not requiring the protein
three-dimensional structure required in traditional SBVS (right), nor limited in scope to a single protein as is the case in LBVS (left). In CGBVS, protein sub-
sequences and chemical descriptions of topology and other physicochemical properties are combined for each known interaction and non-interaction. The set of
(non-)interactions is used to build a predictive model that can rank novel ligand-protein interactions for prioritization in bioassay experiments.
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concept of one-ligand-one-target is simple and easy to under-
stand, it risks narrowing our interpretation of interaction space
to the point where it prohibits us from understanding interaction
space as a whole. In fact, the study with our CGBVS method
successfully uncovered new ligands for multiple protein families
by leveraging existing experimental assays with a representation
appropriate for interaction mining. By incorporating more poly-
pharmacology and chemical biology data, interaction prediction
programs should continue to become more accurate as time
progresses.
The present CGBVS starts with contexts of protein and chem-
ical descriptors (Figure 2). The emerging tools along with the
CGBDD concept will serve as the foundation for a new genera-
tion of drug discovery tools that take extended contexts from
the dual viewpoints of systems biology and systems chemistry
(Figure 3). Systems biology contexts might incorporate pathway
knowledge to model the rules governing a biological network
topology and dynamics. For systems chemistry contexts, we
could utilize building blocks for chemical synthesis as chemical
descriptors, a strategy of fragment-based drug design.Chemistry & BiolFurthermore, it is critical to address how to handle side
effects that come about after molecule design, experiment,
optimization, and mass deployment. Efforts to electronically
accumulate drug adverse event reports have begun only in
the past decade. These data might be beneficial in refining
models about polypharmacology and chemical biology.
Although the ability to perfectly coordinate ligation to receptors
and all downstream signaling events in order to eliminate side
effects is a major challenge, inroads are being made to create
a positive feedback loop for driving signal mechanism model
refinement. Standardized pharmacovigilance methods such
as reporting odds ratios (Hauben and Bate, 2010) are now em-
ployed by governments in analyzing the safety of drugs after
they have reached the market, and we also have made sure
that the clinical information is statistically informative (Ka-
doyama et al., 2011). The upcoming integration of heteroge-
neous knowledge of chemical biology, systems chemistry,
polypharmacology, systems biology, and clinical information,
among others, is an exciting and critical advancement for
intensive acceleration of drug discovery and pharmaceutical
development.ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 27
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